HALIFAX, Jan. 14 /CNW/ - ImmunoVaccine Technologies Inc. (IVT), announced
today that it had signed licensing agreements for Pfizer Animal Health to
apply IVT's novel VacciMax(R) vaccine platform to the potential development of
future, particular livestock vaccines.
Although terms of the agreements were not disclosed, IVT will receive
upfront signing fees, milestone and royalty payments.
"We are excited that Pfizer plans to commercialize our technology," said
Dr. Randal Chase, President and CEO of ImmunoVaccine Technologies. "We look
forward to further discussions with Pfizer to integrate the VacciMax(R)
platform into more applications in the fields of animal health care."
About the VacciMax(R) Platform
The VacciMax(R) vaccine-enhancement platform is comprised of a mixture of
liposomes and adjuvants. The VacciMax(R) platform significantly enhances
antibody production. IVT has demonstrated that the VacciMax(R) platform not
only improves humoral response, but also cell-mediated response (cytotoxic
CTL). This is a novel technology that could aid the development of new
vaccines in human and animal health applications, with potential for both
therapeutic cancer applications and preventative infectious disease vaccines.
In pre-clinical animal models, IVT's research shows that the VacciMax(R)
platform has the ability to greatly enhance the effectiveness of antigens and
could provide a new way to treat a wide range of diseases.
About Pfizer Animal Health
Pfizer, Inc., the world's largest research-based biomedical and
pharmaceutical company, also is a world leader in discovering and developing
innovative animal vaccines and prescription medicines. For additional
information visit www.PfizerAH.com.
ImmunoVaccine Technologies Inc. (IVT) is a clinical stage vaccine
development company focused on commercialization of its novel vaccine
DISCLOSURE NOTICE: The information contained in this release is as of
January 14, 2008. IVT assumes no obligation to update any forward-looking
statements contained in this release as the result of new information or
future events or developments.
This release contains forward-looking information about IVT's
vaccine-enhancement platform, including its potential to aid the development
of new vaccines in human and animal health applications that involves
substantial risks and uncertainties. Such risks and uncertainties include,
among others, the uncertainties inherent in research and development;
decisions by regulatory authorities regarding whether and when to approve any
such vaccines; and competitive developments.
For further information:
For further information: Brian Lowe, Vice President, ImmunoVaccine
Technologies Inc., (902)492-1819, email@example.com; Rick Goulart,
Director of Public Relations, Pfizer Animal Health Inc., (212) 733-7457,
firstname.lastname@example.org; Jennifer Ayotte, Impact Communications, (902)
423-6610 x 315, email@example.com